Literature DB >> 11927619

The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo.

E Helen Kemp1, Elizabeth A Waterman, Brian E Hawes, Kim O'Neill, Raju V S R K Gottumukkala, David J Gawkrodger, Anthony P Weetman, Philip F Watson.   

Abstract

Vitiligo is a common depigmenting disorder resulting from the loss of melanocytes in the skin. The pathogenesis of the disease remains obscure, although autoimmune mechanisms are thought to be involved. Indeed, autoantibodies and autoreactive T lymphocytes that target melanocytes have been reported in some vitiligo patients. The objective of this study was to identify pigment cell antigens that are recognized by autoantibodies in vitiligo. Using IgG from vitiligo patients to screen a melanocyte cDNA phage-display library, we identified the melanin-concentrating hormone receptor 1 (MCHR1) as a novel autoantigen related to this disorder. Immunoreactivity against the receptor was demonstrated in vitiligo patient sera by using radiobinding assays. Among sera from healthy controls and from patients with autoimmune disease, none exhibited immunoreactivity to MCHR1, indicating a high disease specificity for Ab's against the receptor. Inhibition of MCH binding to its receptor by IgG from vitiligo patients was also shown.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11927619      PMCID: PMC150932          DOI: 10.1172/JCI14643

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  32 in total

1.  Direct binding of thyrotropin receptor autoantibody to in vitro translated thyrotropin receptor: a comparison to radioreceptor assay and thyroid stimulating bioassay.

Authors:  N G Morgenthaler; K Hodak; J Seissler; H Steinbrenner; I Pampel; M Gupta; A M McGregor; W A Scherbaum; J P Banga
Journal:  Thyroid       Date:  1999-05       Impact factor: 6.568

2.  The melanin-concentrating hormone receptor couples to multiple G proteins to activate diverse intracellular signaling pathways.

Authors:  B E Hawes; E Kil; B Green; K O'Neill; S Fried; M P Graziano
Journal:  Endocrinology       Date:  2000-12       Impact factor: 4.736

3.  Thyroid autoimmunity.

Authors:  B Rapoport; S M McLachlan
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

4.  Local immune response in skin of generalized vitiligo patients. Destruction of melanocytes is associated with the prominent presence of CLA+ T cells at the perilesional site.

Authors:  R van den Wijngaard; A Wankowicz-Kalinska; C Le Poole; B Tigges; W Westerhof; P Das
Journal:  Lab Invest       Date:  2000-08       Impact factor: 5.662

5.  Autoantibodies to tyrosinase-related protein-1 detected in the sera of vitiligo patients using a quantitative radiobinding assay.

Authors:  E H Kemp; E A Waterman; D J Gawkrodger; P F Watson; A P Weetman
Journal:  Br J Dermatol       Date:  1998-11       Impact factor: 9.302

6.  Molecular characterization of the melanin-concentrating-hormone receptor.

Authors:  Y Saito; H P Nothacker; Z Wang; S H Lin; F Leslie; O Civelli
Journal:  Nature       Date:  1999-07-15       Impact factor: 49.962

7.  Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1.

Authors:  J Chambers; R S Ames; D Bergsma; A Muir; L R Fitzgerald; G Hervieu; G M Dytko; J J Foley; J Martin; W S Liu; J Park; C Ellis; S Ganguly; S Konchar; J Cluderay; R Leslie; S Wilson; H M Sarau
Journal:  Nature       Date:  1999-07-15       Impact factor: 49.962

8.  Selective cloning of allergens from the skin colonizing yeast Malassezia furfur by phage surface display technology.

Authors:  M Lindborg; C G Magnusson; A Zargari; M Schmidt; A Scheynius; R Crameri; P Whitley
Journal:  J Invest Dermatol       Date:  1999-08       Impact factor: 8.551

9.  Autoantibodies to human melanocyte-specific protein pmel17 in the sera of vitiligo patients: a sensitive and quantitative radioimmunoassay (RIA).

Authors:  E H Kemp; D J Gawkrodger; P F Watson; A P Weetman
Journal:  Clin Exp Immunol       Date:  1998-12       Impact factor: 4.330

10.  Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy.

Authors:  T Okamoto; R F Irie; S Fujii; S K Huang; A J Nizze; D L Morton; D S Hoon
Journal:  J Invest Dermatol       Date:  1998-12       Impact factor: 8.551

View more
  26 in total

1.  Patients affected by vitiligo and autoimmune diseases do not show antibodies interfering with the activity of the melanocortin 1 receptor.

Authors:  P Agretti; G De Marco; D Sansone; C Betterle; G Coco; A Dimida; E Ferrarini; A Pinchera; P Vitti; M Tonacchera
Journal:  J Endocrinol Invest       Date:  2010-03-22       Impact factor: 4.256

2.  Case reports: Oral vitiligo.

Authors:  S H Srivathsa
Journal:  Br Dent J       Date:  2015-05-08       Impact factor: 1.626

Review 3.  Highlights in pathogenesis of vitiligo.

Authors:  Ghada F Mohammed; Amal Ha Gomaa; Mohammed Saleh Al-Dhubaibi
Journal:  World J Clin Cases       Date:  2015-03-16       Impact factor: 1.337

Review 4.  Therapeutic implications of autoimmune vitiligo T cells.

Authors:  Kepa Oyarbide-Valencia; Jasper G van den Boorn; Cecele J Denman; Mingli Li; Jeremy M Carlson; Claudia Hernandez; Michael I Nishimura; Pranab K Das; Rosalie M Luiten; I Caroline Le Poole
Journal:  Autoimmun Rev       Date:  2006-05-06       Impact factor: 9.754

5.  Activating autoantibodies against the calcium-sensing receptor detected in two patients with autoimmune polyendocrine syndrome type 1.

Authors:  E Helen Kemp; Nikos G Gavalas; Kai J E Krohn; Edward M Brown; Philip F Watson; Anthony P Weetman
Journal:  J Clin Endocrinol Metab       Date:  2009-10-16       Impact factor: 5.958

6.  Melanin-concentrating hormone as a mediator of intestinal inflammation.

Authors:  Efi Kokkotou; Alan C Moss; Daniel Torres; Iordanes Karagiannides; Adam Cheifetz; Sumei Liu; Michael O'Brien; Eleftheria Maratos-Flier; Charalabos Pothoulakis
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-23       Impact factor: 11.205

7.  Autoantibodies in vitiligo patients are not directed to the melanocyte differentiation antigen MelanA/MART1.

Authors:  E A Waterman; E H Kemp; D J Gawkrodger; P F Watson; A P Weetman
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330

8.  Mechanisms of spatial and temporal development of autoimmune vitiligo in tyrosinase-specific TCR transgenic mice.

Authors:  Randal K Gregg; Lisa Nichols; Yiming Chen; Bao Lu; Victor H Engelhard
Journal:  J Immunol       Date:  2010-01-18       Impact factor: 5.422

9.  An in-depth analysis reveals two new genetic variants on 22q11.2 associated with vitiligo in the Chinese Han population.

Authors:  Xianfa Tang; Hui Cheng; Lu Cheng; Bo Liang; Mengyun Chen; Xiaodong Zheng; Fengli Xiao
Journal:  Mol Biol Rep       Date:  2021-08-04       Impact factor: 2.316

10.  CD8+ T cells from vitiligo perilesional margins induce autologous melanocyte apoptosis.

Authors:  Jilong Wu; Miaoni Zhou; Yinsheng Wan; Aie Xu
Journal:  Mol Med Rep       Date:  2012-10-08       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.